# Genegrow

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/genegrow

- Industry: Biotechnology
- Headquarters: Hangzhou, China
- Website: www.genegrow.bio/
- Latest round: Series A (Sep 5, 2025)
- Investors on record: 4

## About

Established in 2023 and based in Hangzhou, China, Genegrow was founded to advance synthetic biology applications in nutrition and health. Its core offerings include mass-produced astaxanthin, an antioxidant, and L-arginine, an amino acid used in supplements and pharmaceuticals. The company has built an integrated model from R&D to commercialization and distributes products mainly in China, with plans for international expansion. It operates a holding subsidiary, Shandong Jinghong Biotechnology Co., Ltd., which supports the business through feed and food additives. In September 2025, it closed a series A funding round from lead investor Jinding Capital, with participation from Haibang Venture, TTGG Ventures, Dalton Venture and others.

Genegrow develops and manufactures synthetic biology products including astaxanthin, L-arginine, natural pigments, pharmaceutical intermediates, cosmetic ingredients and pesticide intermediates. Its products target industries such as dietary supplements, pharmaceuticals, cosmetics and agriculture.

The company generates revenue primarily through B2B sales of synthetic biology-derived products to health supplement, pharmaceutical, and cosmetic companies. Revenue is supported by bulk sales contracts for key products such as astaxanthin and L-arginine, ect.

Genegrow plans to use its series A funding to accelerate synthetic biology applications in high-end biomanufacturing, scale up industrial production capacity, and expand commercialization efforts in nutraceuticals, pigments, and pharmaceutical intermediates.

## Funding rounds

- Series A, Sep 5, 2025 — TTGG Ventures, Haibang Venture, Jinding Capital, Dalton Venture

## Investors

- TTGG Ventures (https://capitalatlas.ai/funds/ttgg-ventures) — Series A
- Haibang Venture — Series A
- Jinding Capital (https://capitalatlas.ai/funds/jinding-capital) — Series A
- Dalton Venture (https://capitalatlas.ai/funds/dalton-venture) — Series A